Modus
Modus data on sevuparin for CKD to be presented at global GAG symposium
Modus Therapeutics will present new research on sevuparin for chronic kidney disease (CKD) with anemia at the 32nd Symposium on Glycosaminoglycans, held 18–20 September at Villa Vigoni, Italy. The invitation-only event gathers global experts in glycosaminoglycan (GAG) science and clinical innovation.
Preclinical results highlight potential of glycosaminoglycan-based therapy.
Professor Maura Poli of the University of Brescia will deliver the presentation, showcasing joint data from Modus and Brescia. The findings build on results shared at EHA 2025, where sevuparin demonstrated improvements in anemia and kidney function in a validated CKD model.
Preclinical data showed reduced fibrosis and injury markers, with benefits seen both as monotherapy and in combination with erythropoietin. These effects align with sevuparin’s hepcidin-lowering mechanism, reinforcing its potential in CKD-related anemia.
Modus continues to advance its clinical programme. Part 1 of the ongoing phase 2a study in CKD patients with anemia has been completed. Part 2, designed to establish proof-of-concept, is expected to begin in Q4 2025. The company has also presented new data at BioIron and EHA 2025, further supporting sevuparin’s differentiated profile. The molecule’s ability to modulate inflammation and iron regulation is central to its therapeutic promise.
CEO John Öhd said: “With the development of sevuparin, Modus is a pioneer in developing medicines from the unique carbohydrate (sugar)-based group of biomolecules known as glycosaminoglycans (GAGs). Our long-standing research together with leading academic groups shows that sevuparin can modulate key factors that drive inflammation- and iron/hepcidin-dysregulated anemia. Receiving attention at an international GAG summit underscores the molecule’s distinctive profile and clinical potential — and it comes as we move into the next step of our phase 2 program.”
Sevuparin is an acidic, negatively charged, antiadhesive polysaccharide drug The predominant structure of sevuparin with the main monosaccharide constituents. The weight average molecular weight of sevuparin is 6.5–9.5 kDa.
